Lack of Association Between CAG Repeat Polymorphism in the Androgen Receptor Gene and the Outcome of Rheumatoid Arthritis Treatment with Leflunomide

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2011 Oct 15

PMID 21997404

Citations 3

Authors

Violetta Dziedziejko

Mateusz Kurzawski

Krzysztof Safranow

Andrzej Ossowski

Jaroslaw Piatek

Miroslaw Parafiniuk

Dariusz Chlubek

Andrzej Pawlik

Affiliations

Soon will be listed here.

Abstract

Purpose: Leflunomide (LEF) is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA) and the action of which may be modified by sex hormones. The aim of this study was to examine the association between CAG repeat polymorphism in the androgen receptor (AR) gene and the response to treatment with LEF in women with RA.

Methods: We studied 114 women diagnosed with RA and treated with LEF (20 mg daily). Follow-up was 12 months. CAG repeat polymorphism was determined using polymerase chain reaction (PCR) and subsequent fragment analysis by capillary electrophoresis.

Results: Analysis revealed no statistically significant associations between CAG repeat polymorphism in the AR gene and improvement of disease activity parameters: erythrocyte sedimentation rate, serum C-reactive protein, patient's global assessment of disease activity on a visual analog scale (VAS), disease activity score of 28 joints (DAS28), and swollen and tender joint count.

Conclusion: Our results suggest no correlation between CAG repeat polymorphism in the AR gene and response to treatment with LEF in women with RA.

Citing Articles

The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis.

Machaj F, Rosik J, Szostak B, Malinowski D, Safranow K, Oledzka G Clin Rheumatol. 2023; 42(9):2477-2483.

PMID: 37289314 DOI: 10.1007/s10067-023-06653-1.

An Improved Stacked Autoencoder for Metabolomic Data Classification.

Fan X, Wang X, Jiang M, Pei Z, Qiao S Comput Intell Neurosci. 2021; 2021:1051172.

PMID: 34434226 PMC: 8382558. DOI: 10.1155/2021/1051172.

Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics.

Conti V, Corbi G, Costantino M, De Bellis E, Manzo V, Sellitto C Biomolecules. 2020; 10(12).

PMID: 33327600 PMC: 7765045. DOI: 10.3390/biom10121672.

References

Kvien T, Uhlig T, Odegard S, Heiberg M . Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci. 2006; 1069:212-22. DOI: 10.1196/annals.1351.019. View

Gordon D, Beastall G, Thomson J, Sturrock R . Prolonged hypogonadism in male patients with rheumatoid arthritis during flares in disease activity. Br J Rheumatol. 1988; 27(6):440-4. DOI: 10.1093/rheumatology/27.6.440. View

Zitzmann M, Nieschlag E . The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl. 2003; 26(2):76-83. DOI: 10.1046/j.1365-2605.2003.00393.x. View

Schmidt M, Naumann H, Weidler C, Schellenberg M, Anders S, Straub R . Inflammation and sex hormone metabolism. Ann N Y Acad Sci. 2006; 1069:236-46. DOI: 10.1196/annals.1351.021. View

Smolen J, Aletaha D, Koeller M, Weisman M, Emery P . New therapies for treatment of rheumatoid arthritis. Lancet. 2007; 370(9602):1861-74. DOI: 10.1016/S0140-6736(07)60784-3. View

Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M . The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics. 2009; 10(2):303-9. DOI: 10.2217/14622416.10.2.303. View

Castagnetta L, Carruba G, Granata O, Stefano R, Miele M, Schmidt M . Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J Rheumatol. 2004; 30(12):2597-605. View

Cutolo M, Sulli A, Ghiorzo P, Pizzorni C, Craviotto C, Villaggio B . Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis. 2003; 62(4):297-302. PMC: 1754507. DOI: 10.1136/ard.62.4.297. View

Kellner H, Bornholdt K, Hein G . Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. Clin Rheumatol. 2010; 29(8):913-20. PMC: 2895904. DOI: 10.1007/s10067-010-1425-3. View

10.

Dziedziejko V, Kurzawski M, Safranow K, Chlubek D, Pawlik A . The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics. 2010; 12(1):41-7. DOI: 10.2217/pgs.10.164. View

11.

Litinsky I, Paran D, Levartovsky D, Wigler I, Kaufman I, Yaron I . The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine. 2006; 33(2):106-10. DOI: 10.1016/j.cyto.2005.12.009. View

12.

Montagna P, Brizzolara R, Soldano S, Pizzorni C, Sulli A, Cutolo M . Sex hormones and leflunomide treatment of human macrophage cultures: effects on apoptosis. Int J Clin Exp Med. 2009; 2(3):221-32. PMC: 2777270. View

13.

Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F . Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009; 11(1):R7. PMC: 2688237. DOI: 10.1186/ar2591. View

14.

Nelson K, Witte J . Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol. 2002; 155(10):883-90. DOI: 10.1093/aje/155.10.883. View

15.

Dayer J, Cutolo M . Is there a rationale to using leflunomide in early rheumatoid arthritis?. Clin Exp Rheumatol. 2005; 23(3):404-12. View

16.

Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38(6):727-35. DOI: 10.1002/art.1780380602. View

17.

Cutolo M, Capellino S, Montagna P, Villaggio B, Sulli A, Seriolo B . New roles for estrogens in rheumatoid arthritis. Clin Exp Rheumatol. 2004; 21(6):687-90. View

18.

Herrmann M, Schleyerbach R, Kirschbaum B . Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology. 2000; 47(2-3):273-89. DOI: 10.1016/s0162-3109(00)00191-0. View

19.

Miceli-Richard C, Dougados M . Leflunomide for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2003; 4(6):987-97. DOI: 10.1517/14656566.4.6.987. View

20.

Chamberlain N, Driver E, Miesfeld R . The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994; 22(15):3181-6. PMC: 310294. DOI: 10.1093/nar/22.15.3181. View